个人中心 - 老虎社区

Dorash

IP属地：湖北

帖子 · 17帖子 · 17
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- DorashDorash
  ·2021-03-31
  不错
  非常抱歉，此主贴已删除
  1,937 评论
  点赞
  分享
  举报
- DorashDorash
  ·2021-03-24
  文章说q1今年收入1千万
  Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates
  Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consens
  Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates
  2,060 评论
  点赞
  分享
  举报
- DorashDorash
  ·2021-03-24
  为啥这两只刚好是我买入的，目前浮亏一成了！
  非常抱歉，此主贴已删除
  2,454 评论
  点赞
  分享
  举报
- DorashDorash
  ·2020-11-25
  $盈透证券(IBKR)$换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？
  5,022 3
  点赞
  分享
  举报
- DorashDorash
  ·2020-09-21
  本来以为卖了美股就安全了，可是其他a股h也下跌啊
  非常抱歉，此主贴已删除
  2,683 评论
  2
  分享
  举报
- DorashDorash
  ·2020-06-08
  $枫叶教育(01317)$不错不错，值得关注！
  1,832 评论
  4
  分享
  举报
- DorashDorash
  ·2019-12-11
  $中兴通讯(00763)$同为5g概念你为啥不知道涨？看看人家立讯精密！！！
  3,942 1
  2
  分享
  举报
- DorashDorash
  ·2019-12-11
  $小米集团-W(01810)$这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！
  3,678 1
  5
  分享
  举报
- DorashDorash
  ·2019-12-10
  $小米集团-W(01810)$K30在哪里买啊？官网还看不到！
  3,059 2
  2
  分享
  举报
- DorashDorash
  ·2019-12-10
  $小米集团-W(01810)$为啥股价还没有起色？
  1,767 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3464149602391943","uuid":"3464149602391943","gmtCreate":1501055582561,"gmtModify":1502690323634,"name":"Dorash","pinyin":"dorash","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":31,"tweetSize":17,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.14","exceedPercentage":"93.38%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.23%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"湖北","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":354661149,"gmtCreate":1617167599781,"gmtModify":1617167599781,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"不错","listText":"不错","text":"不错","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/354661149","repostId":"1168244531","repostType":2,"isVote":1,"tweetType":1,"viewCount":1937,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":351885004,"gmtCreate":1616584915408,"gmtModify":1616584915408,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"文章说q1今年收入1千万","listText":"文章说q1今年收入1千万","text":"文章说q1今年收入1千万","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/351885004","repostId":"2120700679","repostType":2,"repost":{"id":"2120700679","kind":"news","pubTimestamp":1615930509,"share":"https://www.laohu8.com/m/news/2120700679?lang=&edition=full","pubTime":"2021-03-17 05:35","market":"us","language":"en","title":"Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2120700679","media":"Zacks","summary":"Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consens","content":"<html><body><p>Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.</p>\n<p>This quarterly report represents an earnings surprise of 15.15%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.31 per share when it actually produced a loss of $0.31, delivering no surprise.</p>\n<p>Over the last four quarters, the company has surpassed consensus EPS estimates two times.</p>\n<p>Kindred Bio, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.95 million for the quarter ended December 2020, missing the Zacks Consensus Estimate by 0.94%. This compares to year-ago revenues of $1.4 million. The company has topped consensus revenue estimates two times over the last four quarters.</p>\n<p>The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.</p>\n<p>Kindred Bio shares have added about 13.7% since the beginning of the year versus the S&amp;P 500's gain of 5%.</p>\n<p><b>What's Next for Kindred Bio?</b></p>\n<p>While Kindred Bio has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?</p>\n<p>There are no easy answers to this key question, but <a href=\"https://laohu8.com/S/AONE\">one</a> reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.</p>\n<p>Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.</p>\n<p>Ahead of this earnings release, the estimate revisions trend for Kindred Bio was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.</p>\n<p>It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.33 on $11.9 million in revenues for the coming quarter and -$1.14 on $41.2 million in revenues for the current fiscal year.</p>\n<p>Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.</p>\n<br/>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n<br/> \n<br/>\n<a href=\"https://laohu8.com/S/KIN\">Kindred Biosciences, Inc.</a> (KIN) : Free Stock Analysis Report\n<br/> \n<br/>\nTo read this article on Zacks.com click here.\n<br/> \n<br/>\nZacks Investment Research</body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-17 05:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures ...</p>\n\n<a href=\"https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/88Fg6KE6GPnh0zlh3tqRTA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2120700679","content_text":"Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.\nThis quarterly report represents an earnings surprise of 15.15%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.31 per share when it actually produced a loss of $0.31, delivering no surprise.\nOver the last four quarters, the company has surpassed consensus EPS estimates two times.\nKindred Bio, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.95 million for the quarter ended December 2020, missing the Zacks Consensus Estimate by 0.94%. This compares to year-ago revenues of $1.4 million. The company has topped consensus revenue estimates two times over the last four quarters.\nThe sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\nKindred Bio shares have added about 13.7% since the beginning of the year versus the S&P 500's gain of 5%.\nWhat's Next for Kindred Bio?\nWhile Kindred Bio has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\nThere are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\nEmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\nAhead of this earnings release, the estimate revisions trend for Kindred Bio was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.\nIt will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.33 on $11.9 million in revenues for the coming quarter and -$1.14 on $41.2 million in revenues for the current fiscal year.\nInvestors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n \n\nKindred Biosciences, Inc. (KIN) : Free Stock Analysis Report\n \n\nTo read this article on Zacks.com click here.\n \n\nZacks Investment Research","news_type":1},"isVote":1,"tweetType":1,"viewCount":2060,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":351083321,"gmtCreate":1616545959663,"gmtModify":1616545959663,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"为啥这两只刚好是我买入的，目前浮亏一成了！","listText":"为啥这两只刚好是我买入的，目前浮亏一成了！","text":"为啥这两只刚好是我买入的，目前浮亏一成了！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/351083321","repostId":"2107260553","repostType":2,"isVote":1,"tweetType":1,"viewCount":2454,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":393155907,"gmtCreate":1606265652809,"gmtModify":1703842128908,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IBKR\">$盈透证券(IBKR)$</a>换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？","listText":"<a href=\"https://laohu8.com/S/IBKR\">$盈透证券(IBKR)$</a>换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？","text":"$盈透证券(IBKR)$换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/393155907","isVote":1,"tweetType":1,"viewCount":5022,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3502195913108179","authorId":"3502195913108179","name":"武贤普","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"idStr":"3502195913108179","authorIdStr":"3502195913108179"},"content":"转出来了吗","text":"转出来了吗","html":"转出来了吗"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":975665311,"gmtCreate":1600691907433,"gmtModify":1703822109336,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"本来以为卖了美股就安全了，可是其他a股h也下跌啊","listText":"本来以为卖了美股就安全了，可是其他a股h也下跌啊","text":"本来以为卖了美股就安全了，可是其他a股h也下跌啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/975665311","repostId":"1124902004","repostType":4,"isVote":1,"tweetType":1,"viewCount":2683,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":956339198,"gmtCreate":1591574003714,"gmtModify":1704195947188,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01317\">$枫叶教育(01317)$</a>不错不错，值得关注！","listText":"<a href=\"https://laohu8.com/S/01317\">$枫叶教育(01317)$</a>不错不错，值得关注！","text":"$枫叶教育(01317)$不错不错，值得关注！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/956339198","isVote":1,"tweetType":1,"viewCount":1832,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910518949,"gmtCreate":1576044352981,"gmtModify":1704271128751,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00763\">$中兴通讯(00763)$</a>同为5g概念你为啥不知道涨？看看人家立讯精密！！！","listText":"<a href=\"https://laohu8.com/S/00763\">$中兴通讯(00763)$</a>同为5g概念你为啥不知道涨？看看人家立讯精密！！！","text":"$中兴通讯(00763)$同为5g概念你为啥不知道涨？看看人家立讯精密！！！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/910518949","isVote":1,"tweetType":1,"viewCount":3942,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3537045207544484","authorId":"3537045207544484","name":"27个优质股","avatar":"https://static.tigerbbs.com/fde1daa28cae792e520759bac55bcdd3","crmLevel":2,"crmLevelSwitch":0,"idStr":"3537045207544484","authorIdStr":"3537045207544484"},"content":"大家的所属领域不同，立讯精密是零配件处在行业的顶端，中兴通讯是成品是通信应用处于行业的中游","text":"大家的所属领域不同，立讯精密是零配件处在行业的顶端，中兴通讯是成品是通信应用处于行业的中游","html":"大家的所属领域不同，立讯精密是零配件处在行业的顶端，中兴通讯是成品是通信应用处于行业的中游"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910599969,"gmtCreate":1576035300951,"gmtModify":1704271093586,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！","text":"$小米集团-W(01810)$这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/910599969","isVote":1,"tweetType":1,"viewCount":3678,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910208675,"gmtCreate":1575964746197,"gmtModify":1704730216785,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>K30在哪里买啊？官网还看不到！","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>K30在哪里买啊？官网还看不到！","text":"$小米集团-W(01810)$K30在哪里买啊？官网还看不到！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/910208675","isVote":1,"tweetType":1,"viewCount":3059,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910208155,"gmtCreate":1575964724877,"gmtModify":1704730216094,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>为啥股价还没有起色？","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>为啥股价还没有起色？","text":"$小米集团-W(01810)$为啥股价还没有起色？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/910208155","isVote":1,"tweetType":1,"viewCount":1767,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}